NEWS RELEASE

Teijin, J-TEC and Resilience Form Business Alliance to SpurDevelopment of New Regenerative Medicine Technologies
Tokyo, Japan, April 21, 2023 --- Teijin Limited and Japan Tissue Engineering Co., Ltd.
(J-TEC) announced today that they have entered into a Letter of Intent for a global
strategic collaboration with Resilience US, Inc. (Resilience) to enhance contractdevelopment and manufacturing organization (CDMO) capabilities for cell and genetherapies, including regenerative medicines, to customers in North America and AsiaPacific (APAC).
Teijin, J-TEC and Resilience intend to mutually support and facilitate the expansion of
their clients’ businesses to the respective regions. Resilience would serve as one of thepreferred suppliers and manufacturers to Teijin and J-TEC’s customers for North
America-based process and analytical development (PAD) and biomanufacturing andrefer Teijin and J-TEC for APAC-based PAD and biomanufacturing. In addition,
Resilience would serve as one of the preferred suppliers of viral vectors for use in thedevelopment and manufacture of cell and gene therapy products.
Together, the three companies aim to accelerate development and production of new
manufacturing technologies related to cell and gene therapies, and regenerativemedicines. Additionally, the companies will discuss a cross-licensing arrangement toenable each party to use the other party’s proprietary manufacturing platforms andrelated technology in their home jurisdiction, Japan or North America, as applicable. The
development of preferred clinical trial and regulatory pathways for the companies’customers is also under discussion. The development of preferred clinical trial andregulatory pathways for the companies’ customers in Japan and North America is also
under discussion.
"Teijin, J-TEC, and Resilience are contributing to the provision of innovative medical carethrough manufacturing,’’ said Takayuki Nakano, Ph.D., Mission Executive and General
Manager, Regenerative Medicine & Implantable Medical Device Division of Teijin Limited.
"Teijin and J-TEC will invest in facilities and human resources to meet customer needs,
with a goal of JPY 20 billion in regenerative medicine sales of the Teijin Group by FY
2030, and this collaboration will encourage to achieve this goal.”“We are excited to collaborate with Teijin and J-TEC to envision a future where we could
bring Resilience’s manufacturing capabilities to the Asia-Pacific region,” said Rahul
Singhvi, Sc.D., Chief Executive Officer of Resilience. “Combining Teijin’s engineeringexpertise with our organization’s capabilities in biopharmaceutical manufacturing andmedical innovation can potentially provide customers with transpacific manufacturingsolutions that ensure therapies can be made quickly, safely, and at scale.”
Demand for CDMO services in cell and gene therapies, including regenerative medicines,
is rising due to heightened technical levels in manufacturing and specialization inmanufacturing and development functions. Demand for regenerative medicine market israpidly growing and is estimated to exceed JPY 850 billion in 2030 in Japan. This trend

is assumed to result in increase of regenerative medicine products originated outside
Japan in the Japanese market, making a system that connects development demand
between Japan and outside Japan vital.
Teijin and J-TEC, the Teijin Group’s core regenerative-medicine business, already haveexperience collaborating to support customers. In September 2022 they established aone-stop R&D system with the National Cancer Center Japan and Mitsui Fudosan Co.,
Ltd. in Kashiwanoha Smart City, a life science business park near Tokyo.

Laboratory in Resilience

Teijin's new CMO base (Iwakuni, Japan)
scheduled to start operation in 2024

About the Teijin GroupTeijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions,” Teijin aims to be a company that
supports the society of the future. The group comprises some 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 926.1 billion (USD 7.2 billion) and total assets of JPY 1,207.6 billion (USD9.4 billion) in the fiscal year that ended on March 31, 2022.
About J-TEC
J-TEC (TSE: 7774) is a maker of regenerative medical products whose corporate vision
is “creating a future for regenerative medicine,” and has been a member of the TeijinGroup since March 2021. As Japan’s top runner in regenerative medicine, J-TEC
obtained marketing approval for autologous cultured epidermis “JACE”, Japan’s firstregenerative medical product, in October of 2007, and began marketing the product inJanuary of 2009. J-TEC then went on to obtain marketing approval for Autologous
Cultured Cartilage “JACC” in July of 2012, for Autologous Cultured Corneal Epithelium“Nepic” in March of 2020, and for Autologous Cultured Oral Mucosal Epithelium “Ocural”

in June 2021, and for Autologous Cultured Epidermis Maintaining Melanocytes“JACEMIN” in March 2023. Of the 19 regenerative medical products that have been
approved in Japan, five are J-TEC products. By making the most of the experience andknowhow cultivated through these achievements, J-TEC is engaging in contractdevelopment of regenerative medical products, consulting, and contract manufacture of
specific cell-processed products.
Please visit www.jpte.co.jp/en/
About Resilience
Resilience is a technology-focused biomanufacturing company dedicated to broadening
access to complex medicines (biologics, vaccines, nucleic acid, cell therapy, and genetherapy modalities). Founded in 2020, the company is building a sustainable network ofhigh-tech, end-to-end manufacturing solutions to ensure the treatments of today andtomorrow can be made quickly, safely, and at scale. By continuously advancing thescience of biopharmaceutical manufacturing and development, Resilience seeks to free
its partners to focus on the discoveries that improve patients’ lives and protect
biopharmaceutical supply chains against future disruptions. For more information, visit
https://resilience.com/ and follow us on social media: @IncResilience on Twitter andResilience on LinkedIn.
The Teijin Group Press Contacts
Investor and Public Relations Department
Teijin Limited
pr@teijin.co.jp
Corporate Management Department
Japan Tissue Engineering Co., Ltd.
+81 (0) 533 66 2020
jtec-info@jpte.co.jp
Resilience Media Contact:
Michele Roberts
Head of Communications+16092848213
Michele.roberts@Resilience.com
Resilience Investor Contact:
Tatjana Heller
Head of Investor Relations and Analytics+17745734579
Tatjana.heller@Resilience.com